Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro™ Ellipta ...
Anoro Ellipta (umeclidinium/vilanterol) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD) in adults. Anoro Ellipta comes in one ...
A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration. GlaxoSmithKline's Anoro Ellipta is ...
Anoro Ellipta (umeclidinium and vilanterol inhalation powder) has been approved by the U.S. Food and Drug Administration for once-daily treatment of chronic obstructive pulmonary disease (COPD). COPD, ...
BioWorld - Tuesday, November 21, 2023 See today's BioWorld Home » Anoro Ellipta Briefing Docs Promising Ahead of PADAC Meeting Subscribe to BioWorld™ news services See subscription options To read the ...
Anoro Ellipta (umeclidinium/vilanterol) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). Anoro Ellipta can interact with ...
WASHINGTON, Sept 10 (Reuters) - A federal advisory panel recommended approval of GlaxoSmithKline Plc's new drug to treat chronic obstructive pulmonary disease(COPD ...
AstraZenecaAZN announced disappointing data from a phase IIIb study evaluating Bevespi Aerosphere for treating moderate to very severe chronic obstructive pulmonary disease ("COPD"). The study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results